Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.38 |
| ▸ | FUBP1 | Q96AE4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30515692 | 1.00 | CXCR2 (0.49) | CXCR2ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL3343769 | 0.85 | CXCR2 (0.56) | CXCR2ALDH1A1KDM4ENPC1MAPK1 | |
| SCHEMBL956569 | 0.83 | ABCB1 (0.41) | ADORA2AADORA2BADORA1ADORA3ABCB1 | |
| SCHEMBL954341 | 0.83 | ABCB1 (0.43) | ADORA2AADORA2BADORA1ADORA3ABCB1 | |
| SCHEMBL956154 | 0.83 | FFAR1 (0.40) | CXCR2ADORA2AABCB1FUBP1ALDH1A1 | |
| SCHEMBL958516 | 0.82 | CXCR2 (0.54) | CXCR2ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL956372 | 0.81 | FUBP1 (0.39) | ABCB1FUBP1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL22390007 | 0.80 | CXCR2 (0.42) | CXCR2ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL956581 | 0.80 | CXCR2 (0.57) | CXCR2ALDH1A1KDM4EMEN1ALOX15 | |
| SCHEMBL956304 | 0.80 | CXCR2 (0.72) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | ARDEA BIOSCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | ARDEA BIOSCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| US-10660909-B2 | Method for treating cancer using chemokine antagonists | SYNTRIX BIOSYSTEMS INC. (US) | 2020-05-26 | — | — | US | disclosed |
| WO-2019055509-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20180235964-A1 | CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180177808-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| US-20180177808-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| WO-2017156270-A1 | CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS | ARDEA BIOSCIENCES, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2257552-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009106539-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235964-A1 | CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS | CXCR1, CXCR2, CXCR6 | CXCR2 2/4885ADORA2A 337/4885ADORA2B 1497/4885 |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | CXCR1, CXCR2, CXCR6 | CXCR2 2/4885ADORA2A 1117/4885ADORA2B 3540/4885 |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | CXCR1, CXCR2, CXCR6 | CXCR2 2/4885ADORA2A 330/4885ADORA2B 1313/4885 |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | CXCR1, CXCR2, FPR2 | CXCR2 2/4885ADORA2A 1156/4885ADORA2B 2786/4885 |
| US-20180177808-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS | CXCR1, CXCR2, CXCR5 | CXCR2 2/4885ADORA2A 159/4885ADORA2B 636/4885 |
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885ADORA2A 279/4885ADORA2B 316/4885 |
| US-10660909-B2 | Method for treating cancer using chemokine antagonists | CXCR1, CXCR2, CXCR5 | CXCR2 2/4885ADORA2A 159/4885ADORA2B 636/4885 |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | CXCR1, CXCR2, CXCR6 | CXCR2 2/4885ADORA2A 1117/4885ADORA2B 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.